SERA

Sera Prognostics, Inc. (SERA) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Sera Prognostics, Inc. is a women's health company focused on developing and commercializing blood-based biomarker tests, primarily the PreTRM test, which predicts the risk of preterm birth. The company operates as a single segment and is classified as an emerging growth company and a smaller reporting company.

Key Financial Metrics

Note: All financial figures are in thousands unless otherwise noted.

Material Changes vs. Prior Period

• Revenue: Q2 2025 revenue decreased by $7,000 compared to Q2 2024. However, YTD 2025 revenue increased by $31,000 compared to YTD 2024, driven by deferred revenue recognition from prior agreements.
• Operating Expenses: Total operating expenses remained relatively flat quarter-over-quarter ($9.3 million in Q2 2025 vs. $9.3 million in Q2 2024).
  • R&D: Decreased by $1.1 million in Q2 2025, primarily due to reduced clinical study costs (PRIME study winding down) and lower stock-based compensation.
  • Selling & Marketing: Increased by $0.7 million in Q2 2025 due to strategic hiring of commercial personnel and increased marketing spend in anticipation of PRIME study publication.
  • G&A: Increased by $0.4 million in Q2 2025 due to higher personnel costs.
• Liquidity Event: In February 2025, the company completed an underwritten public offering, raising approximately $53.6 million in net proceeds through the sale of Class A common stock and pre-funded warrants. This significantly bolstered cash reserves.
• Investing Activities: The company invested heavily in marketable securities, with net cash used in investing activities totaling $39.6 million for the six months ended June 30, 2025.

Guidance, Outlook, and Risks

• Commercial Strategy: Management is expanding its commercial team, having hired a Chief Commercial Officer in Q2 2025 and planning to hire field sales representatives in Q3 2025. The strategy focuses on specific geographies to drive adoption of the PreTRM test.
• Clinical Evidence: The company recently presented key results from the PRIME study, showing a 25% reduction in neonatal morbidity and mortality in the modified intent-to-treat population. Full data publication is expected in the coming months. Positive results from the AVERT PRETERM TRIAL were also published in July 2024.
• Cash Runway: Management believes current cash and cash equivalents are sufficient to fund operations through 2028 based on existing plans.
• Risks:
  • Reimbursement: Significant reliance on third-party payer reimbursement; many payers currently do not reimburse for low-risk preterm birth screening.
  • Regulatory: Uncertainty regarding FDA regulation of Laboratory Developed Tests (LDTs), though a recent court decision vacated a final rule that would have imposed stricter requirements.
  • Customer Concentration: Reliance on a limited number of direct customers, including Elevance Health.
  • Capital Needs: Continued need for additional funding to support commercialization and R&D; future equity financing may be dilutive.

Investor Verification Checklist

• Reimbursement Status: Verify current in-network status and reimbursement rates with major commercial payers and Medicaid programs.
• PRIME Study Publication: Monitor the timeline and reception of the full PRIME study data in peer-reviewed journals.
• Commercial Execution: Track the hiring progress of the sales team and early adoption metrics in targeted geographies.
• Capital Structure: Review the terms and exercise status of the 11.25 million pre-funded warrants issued in February 2025.
• Regulatory Landscape: Monitor ongoing legislative and judicial developments regarding FDA oversight of LDTs.